NASDAQ:RDHL - REDHILL BIOPHAR/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.76 -0.09 (-1.02 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$8.76
Today's Range$8.5250 - $8.89
52-Week Range$4.40 - $11.49
Volume34,234 shs
Average Volume65,720 shs
Market Capitalization$186.33 million
P/E Ratio-5.15
Dividend YieldN/A
Beta1.74
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.36 million
Book Value$2.41 per share

Profitability

Net Income$-38,820,000.00
Net Margins-464.35%

Miscellaneous

EmployeesN/A
Market Cap$186.33 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.50). The biotechnology company had revenue of $2.45 million for the quarter, compared to analysts' expectations of $2.14 million. REDHILL BIOPHAR/S had a negative return on equity of 101.35% and a negative net margin of 464.35%. View REDHILL BIOPHAR/S's Earnings History.

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for REDHILL BIOPHAR/S.

What price target have analysts set for RDHL?

3 Wall Street analysts have issued twelve-month price objectives for REDHILL BIOPHAR/S's stock. Their forecasts range from $16.00 to $24.00. On average, they anticipate REDHILL BIOPHAR/S's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 116.9% from the stock's current price. View Analyst Price Targets for REDHILL BIOPHAR/S.

What is the consensus analysts' recommendation for REDHILL BIOPHAR/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for REDHILL BIOPHAR/S.

Has REDHILL BIOPHAR/S been receiving favorable news coverage?

News coverage about RDHL stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. REDHILL BIOPHAR/S earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.

Who are some of REDHILL BIOPHAR/S's key competitors?

What other stocks do shareholders of REDHILL BIOPHAR/S own?

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the folowing people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)
  • Mr. Gilead Raday, Chief Operating Officer (Age 44)
  • Dr. Reza Fathi, Sr. VP of R&D (Age 64)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 43)

Who are REDHILL BIOPHAR/S's major shareholders?

REDHILL BIOPHAR/S's stock is owned by many different of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (17.36%), Ibex Investors LLC (4.41%), Millennium Management LLC (1.42%), Creative Planning (1.33%), FMR LLC (0.94%) and Kepos Capital LP (0.56%).

Which major investors are selling REDHILL BIOPHAR/S stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Kepos Capital LP and D.A. Davidson & CO..

Which major investors are buying REDHILL BIOPHAR/S stock?

RDHL stock was purchased by a variety of institutional investors in the last quarter, including Ibex Investors LLC, FMR LLC, Millennium Management LLC, Creative Planning, 683 Capital Management LLC, D. E. Shaw & Co. Inc., CLARET ASSET MANAGEMENT Corp and Geode Capital Management LLC.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $8.76.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $186.33 million and generates $8.36 million in revenue each year. The biotechnology company earns $-38,820,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

What is REDHILL BIOPHAR/S's official website?

The official website for REDHILL BIOPHAR/S is http://www.redhillbio.com.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 HA`ARBA`A STREET, TEL AVIV L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131.


MarketBeat Community Rating for REDHILL BIOPHAR/S (NASDAQ RDHL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  521
MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: Federal Reserve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel